Clinical trials: Leucovorin
Solid Tumor, Solid Carcinoma
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV)…
- Conditions
- Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer
- Trial name
- MAST (NCT05346484)
- Testing
- CF33-hNIS, Pembrolizumab, Modified FOLFOX
- Where
- 12 sites in United States, Australia
- Volunteers
- 66 people
- Sponsor
- Imugene Limited
Pancreatic Cancer
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
This research study is studying a combination of interventions as a possible treatment for pancreatic tumor. The interventions involved in this study are: FOLFIRINOX which is made up of 4 different drugs: 5-Fluorouracil (5-FU)…
- Trial name
- NCT03563248
- Testing
- FOLFIRINOX, Losartan, Nivolumab
- Where
- 10 sites in United States
- Volunteers
- 168 people
- Sponsor
- Massachusetts General Hospital
Cholangiocarcinoma
Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma
Previous reports suggest benefit of neoadjuvant chemotherapy/chemoradiation treatment for borderline resectable cholangiocarcinoma.
- Trial name
- NCT03603834
- Testing
- mFOLFOXIRI
- Where
- Thailand
- Volunteers
- 25 people
- Sponsor
- Khon Kaen University
Colon Cancer
Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer
The main cause of recurrence after surgical treatment of colon cancer is distant metastasis. Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of chemotherapy.
- Trial name
- NCT03426904
- Testing
- Neoadjuvant FOLFOX, Conventional adjuvant FOLFOX
- Where
- 4 sites in South Korea
- Volunteers
- 708 people
- Sponsor
- Kyungpook National University Hospital
Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
This Phase I/II clinical trial is being conducted at multiple centers to find out whether adding a low dose of EGFR blocking drugs to the standard chemotherapy combination of gemcitabine and nab paclitaxel (GnP) is safe…
- Conditions
- Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm
- Trial name
- PANGEA (NCT06483555)
- Testing
- Gemcitabine, Nab paclitaxel, Erlotinib
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
The purpose of this study is to test any good or bad effects of the study drug called of ibrutinib (also known as Imbruvica™). At this stage of this trial, the study is investigating whether Ibrutinib can be incorporated into the…
- Trial name
- NCT02315326
- Testing
- Ibrutinib, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX)
- Where
- 7 sites in United States
- Volunteers
- 93 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colon Cancer
Study Evaluating Isovorin in Colon Cancer
The purpose of the study is to verify superiority of 1-LV/5FU therapy to UFT Therapy of relapse-free survival time in patients with Dukes C and Cure A colon cancer.
- Trial name
- NCT00195585
- Testing
- Isovorin, UFT
- Where
- Japan
- Volunteers
- 650 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Advanced Solid Tumors
A Study of ABT-165 in Subjects With Solid Tumors
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-165 when administered as monotherapy and in combination with paclitaxel or 5-fluoruracil, folinic acid and…
- Trial name
- NCT01946074
- Testing
- paclitaxel, FOLFIRI, ABT-165
- Where
- 10 sites in United States
- Volunteers
- 101 people
- Sponsor
- AbbVie
Metastatic Colorectal Cancer
Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms
The purpose of this study is to assess FOLFIRI+aflibercept efficacy in patients with or without ACE polymorphisms in terms of Progression-free survival (PFS).
- Trial name
- POLAF (NCT02970916)
- Testing
- FOLFIRI+aflibercept
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Liver Diseases, Hepatocellular Carcinoma
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
This study intends to evaluate the efficacy and safety of blank- microsphere transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (bTAE-HAIC) plus Lenvatinib and…
- Conditions
- Liver Diseases, Hepatocellular Carcinoma, Immunotherapy, Camrelizumab
- Trial name
- NCT06061276
- Testing
- bTAE-HAIC, Lenvatinib, Camrelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Mesothelioma; Peritoneum, Pseudomyxoma Peritonei
Thrombin Generation and Platelet Activation in CRS/HIPEC
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal peroperative chemotherapy (HIPEC), indicated for patients with peritoneal metastases from digestive or gynecological malignancies alike, demonstrates a considerable…
- Conditions
- Mesothelioma; Peritoneum, Pseudomyxoma Peritonei, Peritoneal Carcinomatosis
- Trial name
- NCT03034850
- Testing
- CRS/HIPEC
- Volunteers
- 27 people
- Sponsor
- Ziekenhuis Oost-Limburg
Advanced Colorectal Cancer
A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer
This study adopts a randomized, open-label, positive-controlled, multicenter design, aiming to evaluate the efficacy and safety of SHR-A1811 in combination with chemotherapy and bevacizumab versus standard therapy as first-line…
- Trial name
- NCT07676162
- Testing
- SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Gastroesophageal Adenocarcinoma
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a response-guided approach to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III…
- Trial name
- NCT05733689
- Testing
- FLOT, FOLFOX, FOLFIRI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Irvine
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Unfortunately, despite the best clinical efforts and breakthroughs in biotechnology, most patients diagnosed with pancreatic cancer continue to die from the rapid progression of their disease.
- Conditions
- Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm
- Trial name
- PILLAR (NCT01836432)
- Testing
- FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation
- Where
- 32 sites in United States
- Volunteers
- 302 people
- Sponsor
- NewLink Genetics Corporation
Colon Cancer, Locally Advanced Malignant Neoplasm
Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer
In patients with locally advanced colon cancer (high risk stage II and stage III), curative surgery followed by adjuvant FOLFOX-4 chemotherapy has become the standard of care.
- Trial name
- ECKINOXE (NCT01675999)
- Testing
- Perioperative simplified FOLFOX-4 chemotherapy, Perioperative FOLFOX4+Cetuximab chemotherapy, Surgery followed by FOLFOX4 chemotherapy
- Where
- France
- Volunteers
- 186 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Metastatic Colorectal Cancer (mCRC)
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
This is a multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab biosimilar) and Avastin® with 2 parallel arms to compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin® in combination with FOLFOX…
- Trial name
- NCT02069704
- Testing
- Bevacizumab biosimilar (BEVZ92), Avastin® (bevacizumab, reference product)
- Where
- 18 sites in Argentina, Brazil and 3 more
- Volunteers
- 142 people
- Sponsor
- mAbxience Research S.L.
Recurrent Rectal Cancer, Stage IIA Rectal Cancer
Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer
This phase I trial studies the side effects and best dose of trametinib when given together with fluorouracil and radiation therapy before surgery in treating patients with stage II-III rectal cancer.
- Conditions
- Recurrent Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer
- Trial name
- NCT01740648
- Testing
- trametinib, fluorouracil, radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Pancreatic Cancer
NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer
This is an open label, randomized phase 2 study of NaliCap (irinotecan liposome/Capecitabine) compared to NAPOLI (irinotecan liposome/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer patients.
- Trial name
- NaliCap (NCT04371224)
- Testing
- Irinotecan Liposomal Injection [Onivyde], Capecitabine, 5-fluorouracil
- Where
- 2 sites in South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC)
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS)…
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
- Trial name
- NCT04210115
- Testing
- pembrolizumab, cisplatin, 5-FU
- Where
- 170 sites in United States, Argentina and 25 more
- Volunteers
- 703 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Colorectal Carcinoma
Phase I FOLFOX Combination
A Phase I,open label study to assess the safety and tolerability of ZD6474 in combination with 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) as first and second line therapy in patients with advanced colorectal…
- Trial name
- NCT00499850
- Testing
- ZD6474 (vandetanib), 5-Fluorouracil, Leucovorin
- Where
- 4 sites in Australia
- Volunteers
- 18 people
- Sponsor
- Genzyme, a Sanofi Company